CANbridge Pharmaceuticals (1228 HK)

Analysis

Health Care • China

CANbridge Pharmaceuticals is a global biopharmaceutical company dedicated to the research, development, and commercialization of transformative therapies for rare diseases and oncology. The company offers approved drugs such as Hunterase for Hunter syndrome and Livmarli for Alagille syndrome, and is developing a pipeline of gene therapies and other assets. It was founded in 2012 and is headquartered in Suzhou, China.

Refresh

Company Presentation • 23 Mar 2022 15:30

H2 2021

Company Presentation • 05 Sep 2023 00:00

Corporate Presentation

Company Presentation • 26 Aug 2022 00:00

H1 2022

Company Presentation • 01 Apr 2023 00:00

H2 2022

Company Presentation • 01 Sep 2023 00:00

H1 2023

No more presentations

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00